|
 |
 |
|
|
July 4 2003, Press release
|
|
| Content of information |
| |
 |
FIT Biotech acquired assets of Spectrum Medical Sciences Ltd |
|
Therapeutic trial started with new GTU-MultiHIV vaccine for HIV infected volunteers in Finland |
|
CEO & President became as Deputy Chairman of The Board of Directors |
|
The Board of Directors |
|
Management |
|
| |
| FIT Biotech acquired assets of Spectrum Medical Sciences Ltd |
| |
FIT Biotech Oyj Plc has acquired certain intellectual property rights and all other assets of a vaccine development company Spectrum Medical Sciences Oy, Helsinki, Finland.
The acquisition strengthens FIT Biotech’s vaccine development and production infrastructure by adding several modern equipments to company’s facilities in Tampere and Tarto. By purchasing advanced equipment for gene isolation, amplification and quantitation as well as for bacterial fermentation and DNA purification with liquid chromatography FIT Biotech has multiplied its capacity to isolate and purify DNA as part of the process development.
The acquisition also enables FIT Biotech to potentially continue Spectrum Medical Science’s Meningitis B vaccine development.
|
| |
| Therapeutic trial started with new GTU-MultiHIV vaccine for HIV infected volunteers in Finland |
| |
|
FIT Biotech Plc has started a new multicentre, phase I/II clinical vaccine trial against HIV-1 virus in May 2003. The primary aim of the trial is to evaluate the safety of a DNA vaccine, GTU®-MultiHIV in HIV infected subjects. Altogether 16 subjects will be enrolled and four different dose levels will be evaluated. The multicentre trial sites are located in Helsinki, Tampere and Turku. The Principal Investigator is Professor Annamari Ranki MD, PhD from University of Helsinki and Helsinki University Hospital.
|
| |
| CEO & President became as Deputy Chairman of The Board of Directors |
| |
|
Co-founder and CEO & President Pekka Sillanaukee starts as Deputy Chairman of the Board of Directors and non-executive Director in September 15th, 2003. The new CEO will be appointed during the third quarter of 2003. Dr. Sillanaukee ensures the continuation of the operative business by introducing the new CEO to the company, and then focusing on the business development of the company. Dr. Sillanaukee starts as the President of Bionext Tampere, which is aiming for 100M€ investment and development program for medical biotechnology in Tampere region.
|
| |
| The Board of Directors |
| |
Shareholders meeting in June 12th, 2003 elected followed persons to the Board of Directors and in the Board of Directors meeting in June 18th, 2003 the places were distributed as following:
|
Chairman: Mr. Rabbe Slätis (CEO Karyon Ltd) |
|
Deputy Chairman: Dr. Pekka Sillanaukee (FIT Biotech Plc) |
|
Member: Mr. Erkki Pekkarinen(President & CEO, Bio Fund Management) |
|
Member: Mr. Kai Krohn (FIT Biotech Plc) |
|
Member: Mr. Ulf Rosenlöf (President, Concordia Capital) |
|
Member: Mr. Juha Vapaavuori (Director, Sitra) |
|
| |
| Management |
| |
|
Prof. Kai Krohn, M.D., Ph.D. Senior Vice President, Vaccine Business Area |
|
Ms. Tytti Kärkkäinen, Phil. Lic.Vice. President, Production & Diagnostic Business Area |
|
Ms. Liisa Laitinen, B.Sc. Manager, Adminstration, Human Resources and Cost Control |
|
Mr. Olli-Pekka Leppänen M.D.Vice President, Cardiovascular Device Business Area |
|
Ms. Ilse Piippo, M.D., M.Sc. Vice President, Vaccine Safety & Clinical Development |
|
Dr. Pekka Sillanaukee, Ph.D, eMBA. CEO & President |
|
Ms. Ioana Stanescu, M.Sc. Vice President, Operations, Quality & Regulatory Affairs |
|
Prof. Mart Ustav, Ph.D. Vice President. GTU technology Business Area |
Expert member:
|
Dr. Vesna Blasevic, Ph.D. Senior Scientist, Immunology |
|
| |
| About FIT Biotech |
| |
|
FIT Biotech Plc (www.fitbiotech.com) is an innovative medical biotechnology company engaged in the development and commercialization of its proprietary Gene Transport Unit (GTU®) technology and GTU product applications in DNA vaccination and immune therapy. The company’s other areas of expertise are artificial immunogen (multiepitope), recombinant protein and antibody technologies, and GMP class process development and production for DNA vaccines. In addition, the company has developed and launched diagnostic products for the detection of natural latex allergens. FIT Biotech was established in 1998 and is located in Tampere, Finland, with operations also in Tartu, Estonia.
|
| |
| Further information |
| |
CEO & President Pekka Sillanaukee
FIT Biotech Oyj Plc.
Tel. +358 3 3138 7000
Fax. +358 3 3138 7050
Mobile +358 40 833 1313
pekka.sillanaukee@fitbiotech.com
www.fitbiotech.com
|
|
|
|
|
|
|
 |
|
|
|
 |
|
|
|
|
